Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors
Conditions
Interventions
ALE.P02
Locations
38
United States
Mayo Foundation for Medical Education and Research - Mayo Cl
Scottsdale, Arizona, United States
Providence Medical Foundation
Fullerton, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Yale Comprehensive Cancer Center
New Haven, Connecticut, United States
The University of Chicago Medical Center - Oncology
Chicago, Illinois, United States
Norton Cancer Institue Downtown
Louisville, Kentucky, United States
Start Date
December 16, 2024
Primary Completion Date
February 15, 2028
Completion Date
August 15, 2028
Last Updated
March 3, 2026
NCT06532279
NCT05005403
NCT05047094
NCT06163534
NCT05039801
NCT06980038
Lead Sponsor
Alentis Therapeutics AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions